A Single-center, Randomized, Double-blind, Placebo-controlled, Dose-ascending Phase I Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of Sudapyridine (WX-081) Tablets in Healthy Chinese Subjects
Latest Information Update: 09 Nov 2023
At a glance
- Drugs Sudapyridine (Primary)
- Indications Tuberculosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Shanghai Jiatan Pharmatech
Most Recent Events
- 09 Nov 2023 New trial record